

Infliximab biosimilars for treating inflammatory conditions

Technology Guidance from the MOH Drug Advisory Committee

Guidance Recommendations

The Ministry of Health's Drug Advisory Committee has recommended to:

- ✓ Reclassify infliximab biosimilar (Remsima) 100 mg vial from the Medication Assistance Fund (MAF) to the MOH Standard Drug List (SDL); and
- ✓ List infliximab biosimilar (Ixifi) 100 mg vial on the SDL

in view of favourable cost effectiveness compared to other anti-tumour necrosis factor alfa (anti-TNF α) biologics at the prices proposed by the manufacturers.

Subsidy status

SDL subsidy will apply for all registered indications of infliximab biosimilar 100 mg vial (Remsima and Ixifi) in Singapore:

- Adults with moderately to severely active rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, plaque psoriasis, ulcerative colitis or Crohn's disease;
- Children aged 6 years or older with severe active Crohn's disease; and
- Children aged 6 years or older with moderately to severely active ulcerative colitis.

SDL subsidy **does not** apply to proprietary infliximab 100 mg vial (Remicade) or other brands of infliximab biosimilars.

VERSION HISTORY

Infliximab biosimilars for treating inflammatory conditions

This Version History is provided to track any updates or changes to the guidance following the first publication date. It is not part of the guidance.

- 1. Reclassification of infliximab biosimilar (Remsima) from MAF to SDL**
Date of Publication 18 Jan 2021
- 2. Guidance updated to include infliximab biosimilar (Ixifi) on SDL**
Date of Publication 4 Jan 2022

About the Agency

The Agency for Care Effectiveness (ACE) was established by the Ministry of Health (Singapore) to drive better decision-making in healthcare through health technology assessment (HTA), clinical guidance, and education.

As the national HTA agency, ACE conducts evaluations to inform government subsidy decisions for treatments, diagnostic tests and vaccines, and produces guidance for public hospitals and institutions in Singapore.

This guidance is based on the evidence available to the MOH Drug Advisory Committee as at 15 September 2020 and 26 October 2021. It is not, and should not be regarded as, a substitute for professional or medical advice. Please seek the advice of a qualified healthcare professional about any medical condition. The responsibility for making decisions appropriate to the circumstances of the individual patient remains with the healthcare professional.

Find out more about ACE at www.ace-hta.gov.sg/about

© Agency for Care Effectiveness, Ministry of Health, Republic of Singapore

All rights reserved. Reproduction of this publication in whole or in part in any material form is prohibited without the prior written permission of the copyright holder. Requests to reproduce any part of this publication should be addressed to:

Chief HTA Officer
Agency for Care Effectiveness
Email: ACE_HTA@moh.gov.sg

In citation, please credit the "Ministry of Health, Singapore" when you extract and use the information or data from the publication.